Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Health Information Services

10X Genomics, Inc. operates as a life science and diagnostics company. The Company develops software for analyzing biological systems such as genetic and immune cells. 10X Genomics serves customers worldwide.
Website: 10xgenomics.com



Growth: Bad revenue growth rate -2.0%, there is slowdown compared to average historical growth rates 9.0%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -8.0%

Profitability: LTM EBITDA margin is negative, -9.7%. On average the margin is improving steadily. Gross margin is high, +67.3%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 4.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 148.9% higher than minimum and 71.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.3x by EV / Sales multiple , the company can be 48.1% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.6 mln (-0.029% of cap.)

Key Financials (Download financials)

Ticker: TXG
Share price, USD:  (0.0%)17.77
year average price 12.40  


year start price 16.15 2024-12-09

min close price 7.14 2025-04-08

max close price 20.13 2025-11-24

current price 17.77 2025-12-08
Common stocks: 113 858 684

Dividend Yield:  0.0%
EV / Sales: 2.5x
Margin (EBITDA LTM / Revenue): -9.7%
Fundamental value created in LTM:
Market Cap ($m): 2 023
Net Debt ($m): -395
EV (Enterprise Value): 1 628
Price to Book: 2.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-06seekingalpha.com

10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript

2025-09-10seekingalpha.com

10x Genomics, Inc. (TXG) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-08-09seekingalpha.com

10x Genomics, Inc. (TXG) Q2 2025 Earnings Call Transcript

2025-08-07zacks.com

10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates

2025-07-16newsfilecorp.com

Torex Gold Reports Excellent Drilling Results from EPO

2025-06-18newsfilecorp.com

Torex Gold Announces Results of Its 2025 Meeting of Shareholders

2025-06-17newsfilecorp.com

Torex Gold Resources Inc. (TXG) Closes the Market

2025-05-08seekingalpha.com

10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript

2025-04-10newsfilecorp.com

Torex Gold Reports Q1 2025 Production Results

2025-03-24newsfilecorp.com

Torex Gold Reports First Copper Concentrate Production from Media Luna
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-10-29 2024-08-08 2024-04-30 2024-02-15 2023-11-03 2023-08-04 2023-05-04 2023-02-16 2022-11-03
acceptedDate 2025-11-06 17:36:08 2025-08-07 17:40:53 2024-10-29 16:10:00 2024-08-08 16:12:32 2024-04-30 16:11:02 2024-02-15 17:16:21 2023-11-02 19:27:55 2023-08-03 18:47:02 2023-05-04 17:04:05 2023-02-16 16:48:47 2022-11-02 20:43:58
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 149M 173M 152M 153M 141M 184M 154M 147M 134M 156M 131M
costOfRevenue 49M 48M 45M 46M 45M 78M 58M 47M 36M 37M 30M
grossProfit 100M 125M 106M 107M 96M 106M 96M 100M 98M 119M 101M
grossProfitRatio 0.673 0.723 0.702 0.698 0.678 0.577 0.622 0.678 0.733 0.764 0.768
researchAndDevelopmentExpenses 57M 61M 66M 63M 68M 56M 108M 71M 67M 64M 67M
generalAndAdministrativeExpenses 0 0 0 0 0 83M 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 3M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 75M 74M 82M 83M 85M 86M 82M 92M 83M 79M 73M
otherExpenses 0 -41M 0 -3M -2M 4M -1M -2M -2M 4M 0
operatingExpenses 133M 95M 148M 149M 155M 142M 190M 163M 150M 143M 141M
costAndExpenses 181M 143M 193M 195M 200M 220M 248M 210M 186M 179M 171M
interestIncome 5M 4M 5M 5M 5M 5M 4M 4M 4M 3M 2M
interestExpense 3000 3000 2000 1000 1000 8000 1000 5000 19 000 125 000 114 000
depreciationAndAmortization 12M 10M 11M 11M 11M 12M 3M 12M 2M 7M 75 000
ebitda -16M 47M -24M -26M -48M -24M -92M -61M -50M -16M -40M
ebitdaratio -0.107 0.27 -0.156 -0.201 -0.34 -0.13 -0.597 -0.414 -0.37 -0.104 -0.305
operatingIncome -32M 30M -41M -42M -59M -36M -95M -63M -52M -23M -40M
operatingIncomeRatio -0.216 0.174 -0.274 -0.273 -0.421 -0.194 -0.617 -0.432 -0.387 -0.148 -0.305
totalOtherIncomeExpensesNet 4M 7M 7M 5M 2M -11M -1M -2M 2M 7M -39 000
incomeBeforeTax -28M 37M -34M -37M -58M -47M -92M -61M -50M -16M -40M
incomeBeforeTaxRatio -0.189 0.214 -0.227 -0.242 -0.41 -0.253 -0.597 -0.414 -0.37 -0.105 -0.305
incomeTaxExpense -733 000 2M 1M 818 000 2M 2M 1M 2M 1M 804 000 2M
netIncome -27M 35M -36M -38M -60M -49M -93M -62M -51M -17M -42M
netIncomeRatio -0.184 0.2 -0.236 -0.248 -0.425 -0.266 -0.605 -0.425 -0.378 -0.11 -0.32
eps -0.22 0.28 -0.3 -0.32 -0.5 -0.41 -0.79 -0.53 -0.44 -0.15 -0.37
epsdiluted -0.22 0.28 -0.3 -0.32 -0.5 -0.41 -0.79 -0.53 -0.44 -0.15 -0.37
weightedAverageShsOut 126M 124M 121M 120M 119M 119M 118M 117M 116M 115M 114M
weightedAverageShsOutDil 126M 125M 121M 120M 119M 119M 118M 117M 116M 115M 114M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-10-29 2024-08-08 2024-04-30 2024-02-15 2023-11-03 2023-08-04 2023-05-04 2023-02-16 2022-11-03
acceptedDate 2025-11-06 17:36:08 2025-08-07 17:40:53 2024-10-29 16:10:00 2024-08-08 16:12:32 2024-04-30 16:11:02 2024-02-15 17:16:21 2023-11-02 19:27:55 2023-08-03 18:47:02 2023-05-04 17:04:05 2023-02-16 16:48:47 2022-11-02 20:43:58
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 433M 398M 398M 380M 356M 359M 311M 326M 332M 220M 234M
shortTermInvestments 50M 50M 0 269 000 16M 29M 46M 66M 86M 210M 218M
cashAndShortTermInvestments 482M 447M 398M 380M 372M 389M 357M 391M 418M 430M 452M
netReceivables 97M 119M 84M 91M 91M 115M 104M 88M 78M 104M 84M
inventory 62M 69M 94M 88M 83M 74M 81M 84M 82M 82M 79M
otherCurrentAssets 19M 20M 18M 20M 21M 19M 20M 19M 21M 17M 15M
totalCurrentAssets 660M 656M 594M 579M 567M 596M 562M 583M 602M 635M 629M
propertyPlantEquipmentNet 296M 302M 318M 324M 332M 345M 354M 356M 367M 359M 329M
goodwill 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M
intangibleAssets 65M 15M 16M 17M 16M 17M 22M 22M 23M 23M 23M
goodwillAndIntangibleAssets 69M 19M 21M 21M 21M 21M 26M 27M 27M 27M 28M
longTermInvestments 201 000 0 0 0 0 0 3M 0 0 0 0
taxAssets 0 0 0 0 0 0 -3M 0 0 0 0
otherNonCurrentAssets 2M 3M 5M 5M 3M 3M 6M 24M 18M 7M 10M
totalNonCurrentAssets 368M 324M 344M 351M 356M 369M 386M 407M 412M 394M 367M
otherAssets 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 027M 980M 938M 930M 923M 965M 949M 990M 1 014M 1 029M 996M
accountPayables 18M 16M 26M 21M 20M 16M 19M 23M 29M 22M 22M
shortTermDebt 11M 10M 19M 22M 11M 12M 10M 9M 9M 9M 8M
taxPayables 0 0 4M 6M 6M 5M 4M 2M 2M 4M 3M
deferredRevenue 22M 21M 18M 16M 14M 13M 11M 9M 9M 8M 7M
otherCurrentLiabilities 97M 65M 54M 46M 63M 87M 65M 56M 65M 92M 90M
totalCurrentLiabilities 147M 112M 121M 111M 109M 127M 105M 98M 112M 131M 127M
longTermDebt 76M 77M 76M 79M 81M 84M 88M 90M 93M 86M 88M
deferredRevenueNonCurrent 11M 11M 12M 11M 10M 9M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 -10M -1 0 0 0 0 0
otherNonCurrentLiabilities 6M 6M 5M 5M 14M 4M 10M 8M 7M 6M 57M
totalNonCurrentLiabilities 94M 94M 94M 95M 95M 97M 99M 98M 100M 92M 94M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0
capitalLeaseObligations 76M 87M 86M 89M 81M 84M 98M 100M 102M 95M 96M
totalLiabilities 241M 207M 215M 206M 204M 224M 203M 196M 212M 223M 220M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000
retainedEarnings -1 494M -1 467M -1 418M -1 382M -1 344M -1 284M -1 235M -1 142M -1 080M -1 029M -1 012M
accumulatedOtherComprehensiveIncomeLoss 138 000 220 000 32 000 -430 000 -456 000 -429 000 -677 000 -969 000 -1M -4M -5M
othertotalStockholdersEquity 2 279M 2 240M 2 141M 2 107M 2 064M 2 026M 1 981M 1 937M 1 884M 1 839M 1 793M
totalStockholdersEquity 785M 773M 723M 724M 719M 741M 745M 793M 802M 806M 776M
totalEquity 785M 773M 723M 724M 719M 741M 745M 793M 802M 806M 776M
totalLiabilitiesAndStockholdersEquity 1 027M 980M 938M 930M 923M 965M 949M 990M 1 014M 1 029M 996M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 027M 980M 938M 930M 923M 965M 949M 990M 1 014M 1 029M 996M
totalInvestments 50M 50M 0 269 000 16M 29M 46M 66M 86M 210M 218M
totalDebt 87M 87M 86M 89M 92M 95M 98M 100M 102M 95M 96M
netDebt -346M -311M -312M -290M -264M -264M -213M -226M -230M -125M -138M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-10-29 2024-08-08 2024-04-30 2024-02-15 2023-11-03 2023-08-04 2023-05-04 2023-02-16 2022-11-03
acceptedDate 2025-11-06 17:36:08 2025-08-07 17:40:53 2024-10-29 16:10:00 2024-08-08 16:12:32 2024-04-30 16:11:02 2024-02-15 17:16:21 2023-11-02 19:27:55 2023-08-03 18:47:02 2023-05-04 17:04:05 2023-02-16 16:48:47 2022-11-02 20:43:58
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -27M 35M -36M -38M -60M -49M -93M -62M -51M -17M -42M
depreciationAndAmortization 12M 10M 11M 11M 11M 12M 11M 12M 9M 8M 8M
deferredIncomeTax 0 0 0 0 0 24M -27M 3M 0 0 0
stockBasedCompensation 25M 28M 34M 38M 36M 39M 40M 46M 42M 41M 34M
changeInWorkingCapital 32M -54M 13M -4M -6M 17M 16M -10M -6M -19M -10M
accountsReceivables 7M -66M 8M 122 000 24M -11M -16M -10M 26M -21M -7M
inventory 7M 7M -4M -5M -10M 8M 3M -2M -449 000 -1M -9M
accountsPayables 0 6M 4M 1M 5M -3M -4M 2M -781 000 -224 000 -4M
otherWorkingCapital 18M -858 000 5M -112 000 -24M 24M 34M -413 000 -31M 3M 10M
otherNonCashItems 1M -351 000 64 000 64M 44M -17M 26M 463 000 2M 837 000 660 000
netCashProvidedByOperatingActivities 43M 18M 22M 7M -16M 26M -25M -12M -4M 14M -10M
investmentsInPropertyPlantAndEquipment -687 000 -2M -4M -4M -3M -3M -15M -25M -5M -40M -37M
acquisitionsNet -9M 0 0 0 0 0 0 0 0 -3M -2M
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 -2M -11M
salesMaturitiesOfInvestments 0 50M 271 000 16M 14M 17M 20M 21M 125M 9M 17M
otherInvestingActivites 502 000 -49M 0 -1 000 000 14M 1 20M 0 0 2M 0
netCashUsedForInvestingActivites -9M -939 000 -4M 12M 11M 13M 5M -4M 120M -33M -33M
debtRepayment 0 0 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 -6M 5M 2M 6M 4M 0 2M 21M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 617 000 4M 156 000 5M 2M 8M 4M 0 -6M -16M 2M
netCashUsedProvidedByFinancingActivities 617 000 4M 156 000 5M 2M 6M 4M 7M -3M 5M 2M
effectOfForexChangesOnCash -33 000 360 000 156 000 -3000 -48 000 77 000 -85 000 -49 000 24 000 251 000 -85 000
netChangeInCash 35M 21M 18M 24M -4M 48M -16M -9M 112M -14M -40M
cashAtEndOfPeriod 433M 398M 398M 380M 356M 359M 312M 331M 340M 227M 242M
cashAtBeginningOfPeriod 398M 377M 380M 356M 359M 312M 327M 340M 227M 242M 282M
operatingCashFlow 43M 18M 22M 7M -16M 26M -25M -12M -4M 14M -10M
capitalExpenditure -687 000 -2M -4M -4M -3M -3M -15M -25M -5M -40M -37M
freeCashFlow 43M 16M 18M 4M -19M 22M -41M -37M -9M -26M -46M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-12 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-15 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-29 20:05 ET
10x Genomics Reports Third Quarter 2024 Financial Results
2024-10-15 20:05 ET
10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches
2024-10-09 20:05 ET
10x Genomics Announces Preliminary Select Third Quarter 2024 Results
2024-10-01 20:05 ET
10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting
2024-09-10 13:00 ET
Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer
2024-09-03 20:05 ET
10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research
2024-08-22 20:05 ET
10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-08 20:05 ET
10x Genomics Announces Senior Leadership Changes
2024-08-08 20:04 ET
10x Genomics Reports Second Quarter 2024 Financial Results
2024-08-05 20:00 ET
10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases
2024-07-12 12:00 ET
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024
2024-06-27 13:00 ET
New Insights Into Cleft Palate Unlocked With 10x Genomics' Single Cell and Spatial Technologies
2024-06-20 13:00 ET
10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel
2024-05-29 20:05 ET
10x Genomics Launches 5,000-Plex Gene Panel for Xenium
2024-05-02 20:05 ET
10x Genomics to Present at the BofA Securities 2024 Healthcare Conference
2024-05-01 05:01 ET
Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)
2024-04-30 20:05 ET
10x Genomics Reports First Quarter 2024 Financial Results
2024-04-10 20:05 ET
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
2024-03-26 13:00 ET
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
2024-03-21 20:05 ET
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
2024-03-13 20:05 ET
10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
2024-02-20 21:05 ET
10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference
2024-02-15 21:05 ET
10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
2024-02-07 21:05 ET
10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology
2024-02-05 21:05 ET
10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting
2024-01-24 21:05 ET
10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
2024-01-08 14:00 ET
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
2023-12-21 21:05 ET
10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 21:05 ET
10x Genomics Launches Xenium Catalyst Network
2023-12-19 14:00 ET
Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness
2023-12-13 21:26 ET
High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint
2023-12-07 14:00 ET
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
2023-11-06 21:05 ET
OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
2023-11-02 20:05 ET
10x Genomics Reports Third Quarter 2023 Financial Results
2023-11-01 20:05 ET
10x Genomics to Present at the Stephens 25th Annual Conference
2023-10-26 20:05 ET
Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors
2023-10-11 20:05 ET
10x Genomics to Report Third Quarter 2023 Financial Results on November 2, 2023
2023-09-14 20:36 ET
10x Genomics Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit
2023-09-05 13:00 ET
Study Enabled by 10x Genomics Single Cell and Spatial Technologies Explains Why Immunotherapy is More Effective for Certain Brain Tumors Than Others
2023-08-30 20:05 ET
10x Genomics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-29 20:30 ET
10x Genomics Surpasses 100 Xenium Analyzer Shipments
2023-08-03 20:05 ET
10x Genomics Reports Second Quarter 2023 Financial Results
2023-07-13 20:05 ET
10x Genomics to Report Second Quarter 2023 Financial Results on August 3, 2023
2023-07-05 23:30 ET
CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine
2023-05-24 20:05 ET
10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay
2023-05-03 20:05 ET
10x Genomics Reports First Quarter 2023 Financial Results
2023-04-25 20:06 ET
10x Genomics to Present at the BofA Securities 2023 Healthcare Conference
2023-04-12 20:05 ET
10x Genomics to Report First Quarter 2023 Financial Results on May 3, 2023
2023-02-22 21:30 ET
10x Genomics to Present at the 43rd Annual Cowen Healthcare Conference
2023-02-15 21:05 ET
10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023
2023-02-06 14:00 ET
10x Genomics Demonstrates Breadth, Scale and Leadership at 2023 AGBT General Meeting
2023-01-19 21:05 ET
10x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
2022-12-28 21:05 ET
10x Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-08 21:05 ET
10x Genomics Commercially Launches Xenium Platform for In Situ Analysis
2022-11-09 21:05 ET
10x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor Discovery
2022-11-02 20:05 ET
10x Genomics Reports Third Quarter 2022 Financial Results
2022-10-31 20:05 ET
10x Genomics to Host Investor Day on December 8, 2022
2022-10-12 20:05 ET
10x Genomics to Report Third Quarter Financial Results on November 2, 2022
2022-09-02 20:05 ET
10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-08 20:05 ET
10x Genomics Reports Second Quarter 2022 Financial Results
2022-07-28 20:05 ET
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
2022-07-14 20:06 ET
10x Genomics Names Jim Wilbur as Chief Commercial Officer
2022-07-14 20:05 ET
10x Genomics Announces Preliminary Second Quarter 2022 Revenue
2022-06-07 11:00 ET
10x Genomics Advances Leadership and Innovation in Single Cell and Spatial Technologies at 2022 AGBT General Meeting
2022-05-04 20:05 ET
10x Genomics Reports First Quarter 2022 Financial Results
2022-04-26 20:05 ET
10x Genomics to Present at the BofA Securities 2022 Healthcare Conference
2022-04-14 12:55 ET
10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium
2022-04-07 20:05 ET
10x Genomics to Report First Quarter Financial Results on May 4, 2022
2022-03-01 21:05 ET
10x Genomics to Present at the Cowen 42nd Annual Health Care Conference
2022-02-22 21:15 ET
10x Genomics Showcases Robust Innovation Pipeline at Xperience 2022 Event
2022-02-16 21:05 ET
10x Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022
2022-01-26 21:05 ET
10x Genomics to Report Fourth Quarter and Full Year 2021 Financial Results on February 16, 2022
2022-01-21 14:00 ET
10x Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network
2021-12-22 21:05 ET
10x Genomics to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-01 22:06 ET
10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year
2021-11-03 20:05 ET
10x Genomics Reports Third Quarter 2021 Financial Results
2021-10-25 10:00 ET
10x Genomics Celebrates Opening of Singapore Manufacturing and Commercial Hub
2021-10-07 20:05 ET
10x Genomics to Report Third Quarter Financial Results on November 3, 2021
2021-08-31 20:05 ET
10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-06 12:00 ET
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
2021-08-04 20:05 ET
10x Genomics Reports Second Quarter 2021 Financial Results
2021-07-14 12:00 ET
10x Genomics Introduces New Chromium X Series for Single Cell Analysis
2021-07-07 20:03 ET
10x Genomics to Report Second Quarter Financial Results on August 4, 2021
2021-06-28 07:30 ET
Genuity Science Awarded Designation as a 10x Genomics Certified Service Provider in Single Cell Immune Profiling
ET
10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
ET
10x Genomics Reports Third Quarter 2025 Financial Results
ET
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
ET
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference
ET
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ET
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
ET
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025
ET
Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology
ET
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
ET
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
ET
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
ET
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
ET
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025
ET
10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference
ET
10x Genomics Reports First Quarter 2025 Financial Results
ET
10x Genomics Announces Patent Litigation Settlement Agreement with Bruker
ET
10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025
ET
10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery
ET
10x Genomics to Acquire Scale Biosciences
ET
10x Genomics Reports Second Quarter 2025 Financial Results
ET
10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis
ET
10x Genomics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
ET
CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics
ET
10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025
ET
10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences

SEC forms

Show financial reports only

SEC form 8
2025-11-06 21:08 ET
10X Genomics reported for 2025 q3
SEC form 8
2025-11-06 21:08 ET
10X Genomics published news for 2025 q3
SEC form 10
2025-08-07 21:40 ET
10X Genomics reported for 2025 q2
SEC form 8
2025-08-07 20:10 ET
10X Genomics reported for 2025 q2
SEC form 8
2025-08-07 20:10 ET
10X Genomics published news for 2025 q2
SEC form 10
2025-05-09 00:00 ET
10X Genomics published news for 2025 q1
SEC form 10
2025-05-08 21:35 ET
10X Genomics published news for 2025 q1
SEC form 8
2025-05-08 20:05 ET
10X Genomics reported for 2025 q1
SEC form 8
2025-05-08 20:05 ET
10X Genomics published news for 2025 q1
SEC form 10
2025-02-13 00:00 ET
10X Genomics published news for 2024 q4
SEC form 10
2025-02-12 23:23 ET
10X Genomics published news for 2024 q4
SEC form 8
2025-02-12 16:10 ET
10X Genomics reported for 2024 q4
SEC form 8
2025-02-12 16:10 ET
10X Genomics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
10X Genomics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
10X Genomics published news for 2024 q4
SEC form 10
2024-10-29 16:10 ET
10X Genomics reported for 2024 q3
SEC form 8
2024-10-29 00:00 ET
10X Genomics published news for 2024 q3
SEC form 10
2024-10-29 00:00 ET
10X Genomics reported for 2024 q3
SEC form 8
2024-10-29 00:00 ET
10X Genomics reported for 2024 q3
SEC form 8
2024-10-09 00:00 ET
10X Genomics published news for 2024 q3
SEC form 8
2024-10-09 00:00 ET
10X Genomics published news for 2024 q3
SEC form 10
2024-08-08 16:12 ET
10X Genomics reported for 2024 q2
SEC form 8
2024-08-08 16:08 ET
10X Genomics published news for 2024 q2
SEC form 8
2024-08-08 16:08 ET
10X Genomics reported for 2024 q2
SEC form 8
2024-08-08 16:08 ET
10X Genomics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
10X Genomics reported for 2024 q2
SEC form 10
2024-04-30 16:11 ET
10X Genomics published news for 2024 q1
SEC form 8
2024-04-30 16:06 ET
10X Genomics published news for 2024 q1
SEC form 8
2024-04-30 16:06 ET
10X Genomics reported for 2024 q1
SEC form 10
2024-04-30 00:00 ET
10X Genomics published news for 2024 q1
SEC form 8
2024-02-15 00:00 ET
10X Genomics published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
10X Genomics reported for 2023 q4
SEC form 10
2024-02-15 00:00 ET
10X Genomics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
10X Genomics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
10X Genomics published news for 2023 q4
SEC form 10
2023-11-03 00:00 ET
10X Genomics published news for 2023 q3
SEC form 10
2023-11-02 19:27 ET
10X Genomics published news for 2023 q3
SEC form 8
2023-11-02 16:05 ET
10X Genomics reported for 2023 q3
SEC form 10
2023-08-04 00:00 ET
10X Genomics published news for 2023 q2
SEC form 10
2023-08-03 18:47 ET
10X Genomics published news for 2023 q2
SEC form 6
2023-08-03 16:05 ET
10X Genomics reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
10X Genomics published news for 2023 q2
SEC form 6
2023-07-20 16:05 ET
10X Genomics published news for 2023 q2
SEC form 6
2023-06-16 16:51 ET
10X Genomics published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
10X Genomics published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
10X Genomics published news for 2023 q1
SEC form 10
2023-02-16 16:48 ET
10X Genomics reported for 2022 q4
SEC form 10
2023-02-16 00:00 ET
10X Genomics reported for 2022 q4
SEC form 6
2023-02-15 16:05 ET
10X Genomics published news for 2022 q4
SEC form 8
2023-02-15 00:00 ET
10X Genomics reported for 2022 q4
SEC form 10
2022-11-03 00:00 ET
10X Genomics reported for 2022 q3
SEC form 10
2022-11-02 20:43 ET
10X Genomics reported for 2022 q3
SEC form 6
2022-11-02 16:05 ET
10X Genomics published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
10X Genomics reported for 2022 q3
SEC form 10
2022-08-09 00:00 ET
10X Genomics reported for 2022 q2
SEC form 10
2022-08-08 19:30 ET
10X Genomics reported for 2022 q2
SEC form 6
2022-08-08 16:06 ET
10X Genomics published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
10X Genomics reported for 2022 q2
SEC form 6
2022-08-03 18:59 ET
10X Genomics published news for 2022 q2
SEC form 6
2022-08-03 17:09 ET
10X Genomics published news for 2022 q2
SEC form 6
2022-07-14 16:05 ET
10X Genomics published news for 2022 q2
SEC form 8
2022-07-14 00:00 ET
10X Genomics published news for 2022 q2
SEC form 6
2022-06-17 16:05 ET
10X Genomics published news for 2022 q1
SEC form 10
2022-05-05 16:06 ET
10X Genomics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
10X Genomics reported for 2022 q1
SEC form 6
2022-05-04 16:06 ET
10X Genomics published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
10X Genomics reported for 2022 q1
SEC form 6
2022-04-29 16:07 ET
10X Genomics published news for 2022 q1
SEC form 10
2022-02-18 16:06 ET
10X Genomics published news for 2021 q4
SEC form 10
2022-02-18 00:00 ET
10X Genomics published news for 2021 q4
SEC form 6
2022-02-16 16:05 ET
10X Genomics published news for 2021 q4
SEC form 8
2022-02-16 00:00 ET
10X Genomics published news for 2021 q4
SEC form 10
2021-11-05 16:06 ET
10X Genomics published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
10X Genomics published news for 2021 q3
SEC form 6
2021-11-03 16:05 ET
10X Genomics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
10X Genomics published news for 2021 q3
SEC form 10
2021-08-06 16:05 ET
10X Genomics published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
10X Genomics published news for 2021 q2
SEC form 6
2021-08-04 16:01 ET
10X Genomics published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
10X Genomics published news for 2021 q2
SEC form 6
2021-07-27 06:05 ET
10X Genomics published news for 2021 q2
SEC form 6
2021-06-15 17:01 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-06-01 18:47 ET
10X Genomics published news for 2021 q1
SEC form 10
2021-05-07 16:07 ET
10X Genomics published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-05-05 16:07 ET
10X Genomics published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-04-23 16:10 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-04-23 16:07 ET
10X Genomics published news for 2021 q1
SEC form 10
2021-02-26 16:10 ET
10X Genomics published news for 2020 q4
SEC form 6
2021-02-17 16:06 ET
10X Genomics published news for 2020 q4
SEC form 10
2020-11-12 16:15 ET
10X Genomics published news for 2020 q3
SEC form 6
2020-11-10 16:05 ET
10X Genomics published news for 2020 q3
SEC form 6
2020-10-13 09:21 ET
10X Genomics published news for 2020 q3
SEC form 6
2020-10-05 16:17 ET
10X Genomics published news for 2020 q3